2024 Semi-Annual Report
Announcement on holding the 2024 semi-annual results briefing
Notice on changes in accounting policies
Semi-annual Evaluation Report on the 2024 “Improve Quality, Increase Efficiency, and Focus on Return” Special Action Plan
2024 Semi-Annual Report Summary
Special report on the storage and actual use of funds raised for the 2024 semi-year
Announcement of Resolutions of the Sixth Meeting of the Third Board of Supervisors
Announcement of the resolution of the fifth meeting of the third board of supervisors.
Swhy Securities Underwriting & Sponsorship Co., Ltd's verification opinion on the adjustment of Hangzhou OT Bio-Technology Co., Ltd's temporarily idle raised funds for cash management quota and duration.
Announcement on adjusting the quota and term for temporarily idle raised funds for cash management.
Announcement from Hangzhou Ote Biotechnology Co., Ltd. regarding the invalidation of a portion of the restricted stocks incentive plan for 2022.
Shenzhen Valuation Online Consulting Limited's independent financial advisor report on Hangzhou Otech Biotechnology Co., Ltd.'s 2022 restricted stock incentive plan for the first vesting period reserved for the fulfillment of attribution conditions.
Opinions from the Supervisory Board of Hangzhou Oati Biotechnology Co., Ltd. on checking the list of the first vesting period for the company's 2022 Restricted Stock Incentive Plan.
Hangzhou Ota biotechnology limited company's announcement on 2022 Restricted Stock Incentive Plan reserved for awarding the first vesting period in accordance with the ownership conditions.
Legal opinion from Shanghai Lifei Law Firm regarding the 2022 restricted stock incentive plan grant price adjustment, achievement of the first vesting condition for reserved grants, and cancellation of certain restricted stocks of Hangzhou Autai Biotechnology Co., Ltd.
Announcement of Hangzhou Ota biotechnology co., ltd. on the adjustment of the grant price of the restricted stock incentive plan in 2022.
Announcement of the resolution of the fifth meeting of the third board of directors.
Announcement about the completion of some fund-raising projects and the permanent supplement of surplus raised funds to working capital.
Swhy Securities Sponsorship Co., Ltd.'s verification opinion on the completion of some raised projects of Hangzhou Autobio Biotechnology Co., Ltd. and the permanent supplementation of remaining raised funds for working capital.
Announcement of Annual Equity Distribution Implementation in 2023
No Data